JPS62198615A - Drug for animal - Google Patents
Drug for animalInfo
- Publication number
- JPS62198615A JPS62198615A JP61040406A JP4040686A JPS62198615A JP S62198615 A JPS62198615 A JP S62198615A JP 61040406 A JP61040406 A JP 61040406A JP 4040686 A JP4040686 A JP 4040686A JP S62198615 A JPS62198615 A JP S62198615A
- Authority
- JP
- Japan
- Prior art keywords
- salt
- animal
- drug
- active component
- feed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 title abstract description 11
- 239000003814 drug Substances 0.000 title abstract description 11
- 241001465754 Metazoa Species 0.000 title abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 claims abstract 3
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000000273 veterinary drug Substances 0.000 claims description 2
- 210000003278 egg shell Anatomy 0.000 abstract description 9
- 244000144977 poultry Species 0.000 abstract description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 8
- 239000003651 drinking water Substances 0.000 abstract description 8
- 235000020188 drinking water Nutrition 0.000 abstract description 8
- 102000002322 Egg Proteins Human genes 0.000 abstract description 7
- 108010000912 Egg Proteins Proteins 0.000 abstract description 7
- 235000010323 ascorbic acid Nutrition 0.000 abstract description 4
- 239000011668 ascorbic acid Substances 0.000 abstract description 4
- 229960005070 ascorbic acid Drugs 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- -1 Na salt Chemical class 0.000 abstract description 3
- 229940127226 anticholesterol agent Drugs 0.000 abstract description 2
- 230000037396 body weight Effects 0.000 abstract description 2
- 239000004094 surface-active agent Substances 0.000 abstract description 2
- 239000000454 talc Substances 0.000 abstract description 2
- 229910052623 talc Inorganic materials 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 abstract 1
- 235000013601 eggs Nutrition 0.000 description 6
- 239000002253 acid Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
【発明の詳細な説明】
イ、産業上の利用分野
本発明はＬ−７スコルビン酸−２−リン酸エステルまた
はその塩類を有効成分として含有することを特徴とする
動物用薬剤に関するものである。DETAILED DESCRIPTION OF THE INVENTION A. Field of Industrial Application The present invention relates to a veterinary drug characterized by containing L-7scorbic acid-2-phosphate or its salts as an active ingredient.
口、従来の技術及び問題点
鶏卵産業において卵殻の破損による損害は生産量の５％
以上にも達している。一方、Ｌ−７スコルビン酸には家
禽類の卵殻の厚さの増加による破損防止、卵生産、！ｌ
Ｉｇ重量などを改善する効果があり、ノッケルス（Ｃ，
Ｆ、Ｎｏｃｋｅｌｇ）ら〔ボウルトリーサイエンス（Ｐ
ｏｕｌｔｒｙ ５ｃｉｅｎｃｅ）５２．１８６２〜１８
８７（１９７３） ）による試験の結果など数多く報告
されている。ところが、アスコルビン酸は非常に不安定
であり、水溶液中で特に不安定である他、飼料中に含ま
れる銅などの金属によって酸化されやすく、前出の報告
において飼料中にＬ−アスコルビン酸を１３００ｐｐｍ
以上を配合しても鶏卵の卵殻破損を防止する目的を達成
できていない。Previous technology and problems In the egg industry, damage caused by broken eggshells accounts for 5% of production.
It has reached more than that. On the other hand, L-7 scorbic acid helps prevent breakage due to increased thickness of poultry eggshells, egg production, and! l
It has the effect of improving Ig weight, etc., and Nockels (C,
F., Nockelg) et al. [Boultry Science (P.
ultry 5science) 52.1862~18
87 (1973)) have been reported. However, ascorbic acid is extremely unstable, especially in aqueous solutions, and is easily oxidized by metals such as copper contained in feed.
Even if the above ingredients are blended, the purpose of preventing eggshell breakage of chicken eggs cannot be achieved.
ハ６問題点を解決するための手段
上記の事情にかんがみ１本発明者らは安定で、かつ、少
量で卵殻の破損を防止する動物用薬剤の研究を重ねた結
果、Ｌ−アスコルビン酸−２＝リン酸エステルまたはそ
の塩類、例えばナトリウム、カリウム、カルシウム、マ
グネシウム塩等を家禽類の飼料又は飲料水に添加した場
合にも極めて安定であり、飼料ＩＫｇ又は飲料水１見中
にｏ、ｏｉ〜０．５ ミリモルを添加することに上り家
禽類の卵殻の破損防止の他、卵生産・卵白蛋白の増加な
ど卵生産の改善に充分な効果を示すことを発見し、本発
明を完成した。C.6 Means for Solving Problems In view of the above circumstances, the present inventors have repeatedly conducted research on animal drugs that are stable and prevent eggshell damage in small amounts, and have found that L-ascorbic acid-2 = Extremely stable even when phosphate esters or their salts, such as sodium, potassium, calcium, and magnesium salts, are added to poultry feed or drinking water; The present invention was completed based on the discovery that adding 0.5 mmol of the product is effective in preventing damage to poultry eggshells, as well as improving egg production, such as increasing egg production and egg white protein.
さらに、本発明中の化合物は、家禽類を含めて動物用の
抗コレステロール剤又は保健薬としても有効であること
が認められた。Furthermore, the compounds of the present invention have been found to be effective as anticholesterol agents or health drugs for animals including poultry.
すなわち、本発明は飼料中又は飲料水中で極めて安定で
かつアスコルビン酸活性を有する動物用薬剤を提供する
ものである。That is, the present invention provides an animal drug that is extremely stable in feed or drinking water and has ascorbic acid activity.
本発明の関する前記化合物の有効投与量は家禽類の卵殻
破損防止、非品質の改善のためには前述のとおり、飼料
ＩＫｇ又は飲料水ＩＪＩ中に本発明の有効成分を０．０
１〜０．５ミリモル使用するが、動物用の抗コレステロ
ール剤又は保健薬の場合には家禽類の体重ＩＫｇ当り
０．００３〜０．０３ミリモルフ日投与すれば充分であ
る。投与の方法としては有効成分をタルク、界面活性剤
等に配合して、一旦配合用薬剤を作りこれを飼料、飲料
水に添加することもできるし、注射剤として投与するこ
ともできる。また他の動物用抗菌剤、抗原虫剤、抗ヒス
タミン剤、消炎剤と併用することもできる。The effective dose of the compound according to the present invention is to prevent poultry eggshell breakage and improve quality, as described above, by adding 0.0 kg of the active ingredient of the present invention to IKg of feed or IJI of drinking water.
1 to 0.5 mmol is used, but in the case of anti-cholesterol drugs or health drugs for animals, it is used per kg of poultry weight.
Administration of 0.003 to 0.03 mmolf per day is sufficient. As for the method of administration, the active ingredient can be mixed with talc, a surfactant, etc. to make a compounded drug, which can be added to feed or drinking water, or it can be administered as an injection. It can also be used in combination with other veterinary antibacterial agents, antiprotozoal agents, antihistamines, and anti-inflammatory agents.
二９発明の効果
実施例を挙げて１本発明をさらに具体的に説明するが本
発明はこれにより制限されるものではない。EXAMPLE 29 The present invention will be described in more detail with reference to Examples, but the present invention is not limited thereto.
実施例１
生後５０週令の白色レグホン種の酸４００羽を １００
羽ずつ４区に分け、各々の区に１表１に示す基本飼料Ｉ
Ｋｇに対し、Ｌ−７スコルビン酸を ０．１ミリモル、
本発明の化合物、Ｌ−７スコルビン酸−２−リン酸エス
テルマグネシウム塩、Ｌ−アスコルビン酸−２−リン酸
エステルカルシウム塩を夫々、Ｌ−７スコルビン酸換算
で０．１ミリモルを添加して食餌した。添加物質はいず
れも給餌開始の５０日前に基本飼料に添加し、室温で貯
蔵した。Example 1 100 400 50-week-old White Leghorn birds
Divide each wing into 4 sections, and feed each section with 1 basic feed I shown in Table 1.
0.1 mmol of L-7 scorbic acid per kg
The compound of the present invention, L-7 scorbic acid 2-phosphate magnesium salt, and L-ascorbic acid 2-phosphate ester calcium salt were added to the diet in an amount of 0.1 mmol calculated as L-7 scorbic acid. did. All additive substances were added to the basal diet 50 days before the start of feeding and stored at room temperature.
但し、ミネラルは飼料１００ ｇ当り、ビタミンＡ：４
４０１、Ｕ、、ビｐ ミｙＤ ： ５０１．Ｕ、、
リボフラビン：０．２２ ｔａｇ、パントテン酸： ０
．４Ｅｌ ｔａｇ 、ピリドキシン： ０．２９ ｍｇ
、葉酸： ０．０２４ ｍｇとした。給餌開始の５
０日口の全ての産卵を採取し、卵殻の厚さを測定し、各
区毎の平均値を求めて表２に示した。However, minerals include vitamin A: 4 per 100 g of feed.
401, U,, BipmyD: 501. U...
Riboflavin: 0.22 tag, pantothenic acid: 0
．． 4El tag, pyridoxine: 0.29 mg
, folic acid: 0.024 mg. Feeding start 5
All eggs laid on day 0 were collected, the thickness of the eggshell was measured, and the average value for each group was calculated and shown in Table 2.
（以下余白）
表 １
表 ２
表２で明らかなように、本発明中の化合物を添加した区
では、卵殻の厚さは無処理区より１０５以上増加し、Ｌ
−アスコルビン酸添加区にもまさっていた。(Margins below) Table 1 Table 2 As is clear from Table 2, in the plots to which the compound of the present invention was added, the eggshell thickness increased by 105 or more compared to the untreated plots, and L
-It was superior to the ascorbic acid added group.
実施例２
Ｌ−アスコルビン酸−２−リン酸エステルマグネシウム
塩を１見の水道水に０．１ミリモルの割合（３７，９ｐ
ｐｍ ）で溶解し、これを飲料水として家禽類に与える
。Example 2 L-ascorbic acid-2-phosphate ester magnesium salt was added at a ratio of 0.1 mmol (37.9p) to one glass of tap water.
pm) and give this to poultry as drinking water.
実施例３
Ｌ−７スコルビン酸−２−リン酸エステルマグネシウム
を１０％の濃度になるように生理食塩水に溶解後、バイ
ヤル瓶に充填する。使用時にはこれを滅菌水で稀釈し、
１回あたりの投与量が体重ＩＫｇあたり０．Ｏｌミリモ
ルになるように動物に注射する。Example 3 Magnesium L-7 scorbic acid-2-phosphate is dissolved in physiological saline to a concentration of 10% and then filled into a vial. When using it, dilute it with sterile water,
The dose per dose is 0.0 kg per kg of body weight. Inject the animal with 1 mmol of Ol.
Claims (1)
類を有効成分として含有することを特徴とする動物用薬
剤。A veterinary drug characterized by containing L-ascorbic acid-2-phosphate or a salt thereof as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61040406A JP2547400B2 (en) | 1986-02-27 | 1986-02-27 | Veterinary drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61040406A JP2547400B2 (en) | 1986-02-27 | 1986-02-27 | Veterinary drug |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8068219A Division JP2874633B2 (en) | 1996-03-25 | 1996-03-25 | Feed additives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62198615A true JPS62198615A (en) | 1987-09-02 |
| JP2547400B2 JP2547400B2 (en) | 1996-10-23 |
Family
ID=12579778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61040406A Expired - Lifetime JP2547400B2 (en) | 1986-02-27 | 1986-02-27 | Veterinary drug |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2547400B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1046345A3 (en) * | 1999-04-23 | 2002-07-10 | Showa Denko Kabushiki Kaisha | Preparation for administration to animals and feeding method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4924783A (en) * | 1972-06-29 | 1974-03-05 | ||
| JPS51125756A (en) * | 1974-11-21 | 1976-11-02 | Kumiai Chem Ind Co Ltd | A drug for animals |
| JPS52136160A (en) * | 1976-05-06 | 1977-11-14 | Univ Kansas State | Preparation of phosphoric ester of ascorbic acid |
| JPS6041611A (en) * | 1983-08-17 | 1985-03-05 | Sankyo Co Ltd | Blood lipid improving agent |
-
1986
- 1986-02-27 JP JP61040406A patent/JP2547400B2/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4924783A (en) * | 1972-06-29 | 1974-03-05 | ||
| JPS51125756A (en) * | 1974-11-21 | 1976-11-02 | Kumiai Chem Ind Co Ltd | A drug for animals |
| JPS52136160A (en) * | 1976-05-06 | 1977-11-14 | Univ Kansas State | Preparation of phosphoric ester of ascorbic acid |
| JPS6041611A (en) * | 1983-08-17 | 1985-03-05 | Sankyo Co Ltd | Blood lipid improving agent |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1046345A3 (en) * | 1999-04-23 | 2002-07-10 | Showa Denko Kabushiki Kaisha | Preparation for administration to animals and feeding method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2547400B2 (en) | 1996-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4153689A (en) | Stable insulin preparation for nasal administration | |
| EP0139534B1 (en) | Compositions for the prophylactic treatment of osteitis and osteomyelitis | |
| JPH01160917A (en) | Origomer of 3-hydroxybutanic acid, ester of said acid and pharmaceutical composition of derivative of hydroxybutanic acid selected from ester of said oligomer and 3-butanediol | |
| US4185093A (en) | Preparation and method for treatment of hypocalcemia, hypophosphatemia and downer cow syndrome in animals | |
| JPS62198615A (en) | Drug for animal | |
| Davis | Fluorides: A Critical Review: V. Fluoride Intoxication in Laboratory Animals | |
| US5348749A (en) | Method for treating panic disorder | |
| Stokstad et al. | Absence of appreciable L. casei factor effect in anti-pernicious anemia liver extract | |
| US4192865A (en) | Sedative preparation for animals and method | |
| US3655882A (en) | Stable dietary supplement for new born pigs | |
| US3152041A (en) | Piperazine-bithionol anthelmintic | |
| US3532791A (en) | N,n'-ethylenebis(2-(o-hydroxyphenyl)glycine) | |
| US2449080A (en) | Composition for control of poultry coccidiosis | |
| JPS62126130A (en) | Medicinal composition for animals | |
| US3055805A (en) | Process of treating acidosis with t.h.a.m. | |
| JP6856813B1 (en) | Zinc Intravenous Infusion Formulation | |
| US3639606A (en) | Method for the prevention or cure of oxalic lithiasis and pharmaceutical compositions therefor | |
| US2653901A (en) | Adenylic acid salts-gelatin composition | |
| US2892752A (en) | Method of treating worms in ruminants | |
| US3956503A (en) | Composition for the treatment and the prevention of heliencephalitis, thermoplegia and other disorders in domestic animals and poultry | |
| US3224939A (en) | Method for treating helminthic infections | |
| CN1843364A (en) | Pharmaceutical for preventing and treating coccidiosis, and its usage method | |
| US3829566A (en) | Method for control of white muscle disease | |
| Thayer et al. | Potencies of Vitamin Ki and of 2-Methyl-1, 4-Naphthoquinone | |
| Levey | Effect of Ascorbic Acid, d-Isoascorbic Acid and Glucoascorbic Acid on Cobalt Polycythemia in the Rat and Rabbit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |